Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 5/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445932 | 0.99 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL1055639 | 0.96 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL443099 | 0.96 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL445843 | 0.93 | SMN1; SMN2 (0.78) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL445581 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL4257478 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL4255664 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL445225 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL445226 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 | |
| SCHEMBL443732 | 0.83 | NPC1 (0.66) | SMN1; SMN2RAB9AKMT2AHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | LES LABORATOIRES SERVIER SAS (FR) | 2014-11-20 | — | — | US | claimed |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| CN-1768031-A | hydroxamates as therapeutic agents | AXYS PHARM INC (US) | 2006-05-03 | — | — | CN | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | PHARMACYCLICS LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9492423-B2 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | PHARMACYCLICS LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9403032-B2 | Formulations of histone deacetylase inhibitor and uses therof | PHARMACYCLICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150335609-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | PHARMACYCLICS LLC | 2015-11-26 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20080248506-A1 | Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1768031-A | hydroxamates as therapeutic agents | AXYS PHARM INC (US) | 2006-05-03 | — | — | CN | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | SMN1; SMN2 3363/4885RAB9A 4162/4885KMT2A 90/4885 |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 1502/4885RAB9A 2589/4885KMT2A 51/4885 |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 1502/4885RAB9A 2589/4885KMT2A 51/4885 |
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | HDAC5, HDAC7, HDAC4 | SMN1; SMN2 968/4885RAB9A 1451/4885KMT2A 26/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | SMN1; SMN2 4389/4885RAB9A 4653/4885KMT2A 249/4885 |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 1502/4885RAB9A 2589/4885KMT2A 51/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885RAB9A 4301/4885KMT2A 263/4885 |
| US-20150335609-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | HDAC3, HDAC5, HDAC4 | SMN1; SMN2 2348/4885RAB9A 1801/4885KMT2A 43/4885 |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | HDAC1, HDAC7, HDAC5 | SMN1; SMN2 1502/4885RAB9A 2589/4885KMT2A 51/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | SMN1; SMN2 3363/4885RAB9A 4162/4885KMT2A 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.